Freenome

“I could see a Pfizer buying Omada, you know, and maybe coupling with a drug or maybe not. I could see Google buying a company like Omada. I could see Freenome being bought either by a therapeutics company that wants a diagnostic, or by, let's say, a sequencing…”

“Freenome's test that's something that you could do once a year, you could do twice a year, it's comparable to the cost of the dentist, and something where one could catch cancer immediately, like catching a cavity at a very early stage, and it gets cured, and …”

“So a company like Freenome will use machine learning and deep learning with genomics to be able to tell whether you have cancer early enough, such that the cure rate, success rate could be 80%, a hundred percent.”

“The company Freenome is working on a cancer diagnostic by reading the DNA that's free floating in your bloodstream.”

“And so if you think about the game plan that Freenome runs for taking blood and understanding where there's cancer and what's the cancerous agents in there, what BioAge is doing is doing essentially the same thing, looking at the blood of young, using machine …”

“Companies like Freenome that look for the signals for cancer from blood can do considerably better. You know, 90% and plus.”

“The underlying biology should theoretically enable us to detect any diseases where there is an immune change.”

“What we're detecting is DNA fragments that are actually coming from the immune cells that are turning over in your body.”

“Because we can now make a diagnostic that's fundamentally AI-based, even after we launch the test into the market, we can actually work with our partners to get results of the test that we sell back so that we can teach the artificial intelligence that it made…”